Patents: Nyxoah Obtains a Default Decision Against Inspire Medical in Munich
The legal dispute between Nyxoah and Inspire Medical Systems has reached a new stage. The Belgian company has made public a favorable decision handed down in Munich by the European patent court, in a press release dated November 18, 2026, issued under inside information disclosure rules.
The specialist in neurostimulation for obstructive sleep apnea said it is currently examining all possible enforcement options.
A Patent Infringement Action Concerning European Patent 2 760 534
The Court of First Instance of the Unified Patent Court (Juridiction unifiée du brevet), sitting in Munich, Germany, issued a default decision in favor of Nyxoah.
The proceedings were initiated by the company from Mont-Saint-Guibert, which brought a patent infringement action before this court against Inspire Medical Systems. The action concerns European patent 2 760 534, held by Nyxoah.
A Final Outcome Listed by Nyxoah Among Its Uncertainties
In the section devoted to its forward-looking statements, Nyxoah lists "the final outcome of any legal action or judicial proceeding between Nyxoah and Inspire Medical Systems" among the factors subject to risks and uncertainties. The company itself therefore presents the outcome of the dispute as not definitively established.
Listed on Euronext Brussels and on the Nasdaq, Nyxoah markets the Genio system, a hypoglossal nerve neurostimulation therapy that is leadless and batteryless. The device has held CE marking since 2019 and was approved by the FDA in August 2025.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 23,2 millions d'euros
Quarterly revenue: 23,2 millions d'euros
Revenue growth: 430,6 %
Net income: -66,7 millions d'euros
Guidance from the release
« The Company expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million. »
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: « The Company expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million. »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.